Ignite Creation Date:
2025-12-24 @ 5:57 PM
Ignite Modification Date:
2025-12-30 @ 3:12 AM
Study NCT ID:
NCT02227368
Status:
TERMINATED
Last Update Posted:
2017-07-19
First Post:
2014-08-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Peripheral Artery Disease (PAD) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Myocardial Infarction | View |
| None | Peripheral Arterial disease | View |
| None | Mycardial Ischemia | View |
| None | Heart Diseases | View |
| None | Cardiovascular Diseases | View |
| None | Vascular Diseases | View |
| None | Altherosclerosis | View |
| None | Arteriosclerosis | View |
| None | Arterial Occlusive Diseases | View |
| None | Peripheral Vascular Diseases | View |
| None | Ticagrelor | View |
| None | Ticlopidine | View |
| None | Platelet Aggregation inhibitors | View |
| None | Hematologic Agents | View |
| None | Therapeutic Uses | View |
| None | Pharmacologic Actions | View |
| None | Purinegic P2Y Receptor Antagonists | View |
| None | Purinegic P2 Receptor Antagonists | View |
| None | Purinergic Antagonists | View |
| None | Purinergic Agents | View |
| None | Neurotransmitter Agents | View |
| None | Molecular Mechanisms of Pharmacological Actions | View |
| None | Physiological Effects of Drugs | View |
| None | Fibrinolytic Agents | View |
| None | Crardiovascular Agents | View |